EPURE Transplant (Eplerenone in Patients Undergoing Renal Transplant) study: study protocol for a randomized controlled trial
Authors:
- Sophie GirerdSGSophie Girerd
- Luc FrimatLFLuc Frimat
- Didier DuclouxDDDidier Ducloux
- Yannick Le MeurYMYannick Le Meur
- Christophe MariatCMChristophe Mariat
- Bruno MoulinBMBruno Moulin
- Christiane MoussonCMChristiane Mousson
- Philippe RieuPRPhilippe Rieu
- Nassim Dali-YoucefNDNassim Dali-Youcef
- Ludovic MerckleLMLudovic Merckle
- Xavier LepageXLXavier Lepage
- Patrick RossignolPRPatrick Rossignol
Open Access
- 30 October 2018
- journal article
- research article
- Published by Springer Nature in Trials
- Vol. 19 (1) , 1-10
Abstract
Despite advances in immunosuppressive therapy, kidney graft survival has failed to improve during the last decades. Ischemia/reperfusion injury (IRI) is one of the main pathophysiological mechanisms underlying delayed graft function, which is associated with poor long-term graft survival. Due to organ shortage, the proportion of grafts from expanded criteria donors (ECDs) is ever growing. These grafts may particularly benefit from IRI prevention. In preclinical models, mineralocorticoid receptor antagonists (MRAs) have been shown to efficiently prevent IRI. This study aims to assess the effect of MRA administration in the early phase of kidney transplantation (KT) among recipients of ECD grafts on mid-term graft function. This is a multicenter, double-blind, placebo-controlled, randomized clinical trial. Patients on hemodialysis and undergoing a single or a dual KT from an ECD will be eligible for inclusion. We plan to randomize 132 patients. Included patients will be randomized (1:1) to receive either eplerenone 25 mg every 12 h during 4 days (the first dose being administered just prior to KT) or placebo. The primary outcome is graft function at 3 months, assessed by glomerular filtration rate (GFR, in mL/min/1.73m2) measured using iohexol clearance. Secondary outcomes include (1) proportion of patients with either dialysis dependency or a GFR < 30 mL/min/1.73m2 at 3 months, (2) proportion of patients with immediate, slow, or delayed graft function, (3) proteinuria at 3 months, (4) occurrence of hyperkalemia during the first week following KT, (5) length of hospital stay for the KT, and (6) occurrence of biopsy-proven acute rejection in the first 3 months following KT. Estimated GFR, graft, and patient survival will also be collected at 1, 3, and 10 years via the national database of organ recipients. Improvement of ECD grafts is a public health priority, since better ECD outcomes could eventually limit organ shortage. MRA administration in the early phase of KT may prevent IRI and subsequently improve mid-term graft function. The trial will also assess the safety of MRA administration in this population, primarily the absence of threatening hyperkalemia. ClinicalTrials.gov, NCT02490904 . Registered on 1 July 2015.Keywords
Funding Information
- French Ministry of Health
This publication has 45 references indexed in Scilit:
- Reporting and analysis of trials using stratified randomisation in leading medical journals: review and reanalysisBMJ, 2012
- Eplerenone in Patients with Systolic Heart Failure and Mild SymptomsNew England Journal of Medicine, 2011
- Long-term graft function changes in kidney transplant recipientsClinical Kidney Journal, 2010
- Pharmacokinetics of Eplerenone After Single and Multiple Dosing in Subjects With and Without Renal ImpairmentThe Journal of Clinical Pharmacology, 2005
- Comparison of Mortality in All Patients on Dialysis, Patients on Dialysis Awaiting Transplantation, and Recipients of a First Cadaveric TransplantNew England Journal of Medicine, 1999
- The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart FailureNew England Journal of Medicine, 1999
- Early prediction of renal allograft loss beyond one yearTransplant International, 1993
- Early prediction of renal allograft loss beyond one yearTransplant International, 1993
- Measurement of Renal Function with IohexolInvestigative Radiology, 1990
- A Simple Method for the Determination of Glomerular Filtration RateScandinavian Journal of Clinical and Laboratory Investigation, 1972